CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
3.755
+0.045 (1.21%)
Apr 29, 2026, 10:28 AM EDT - Market open
CervoMed Revenue
In the year 2025, CervoMed had annual revenue of $4.01M, down -58.86%. CervoMed had revenue of $8.73K in the quarter ending December 31, 2025, a decrease of -99.60%.
Revenue (ttm)
$4.01M
Revenue Growth
-58.86%
P/S Ratio
8.57
Revenue / Employee
$267,101
Employees
15
Market Cap
34.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.01M | -5.73M | -58.86% |
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veru Inc. | 16.89M |
| Palatin Technologies | 8.96M |
| Evaxion | 7.53M |
| Pluri | 1.34M |
| RenovoRx | 1.12M |
| INmune Bio | 50.00K |
| Senti Biosciences | 22.00K |
CRVO News
- 7 days ago - CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - GlobeNewsWire
- 22 days ago - CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - GlobeNewsWire
- 5 weeks ago - CervoMed Transcript: The 38th Annual Roth Conference - Transcripts
- 5 weeks ago - CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology - GlobeNewsWire
- 6 weeks ago - CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies - GlobeNewsWire
- 2 months ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 5 months ago - CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewsWire